Unveiling PIK3CA mutation: a prognostic beacon in endometrial carcinoma and its immune implications
Our study highlighted the potential of <i>PIK3CA</i> mutation as a biomarker for stratifying EC patients and tailoring therapeutic strategies, particularly in the context of immune checkpoint inhibitors. Future research should focus on elucidating the mechanistic role of <i>PIK3CA</i> in EC pathogenesis and its interaction with the tumor microenvironment (TME) to optimize patient outcomes.
Authors
- Peiqi Jia
- Shuai Cao (ORCID: https://orcid.org/0000-0002-5938-9693)
- Junhong Zhuang
- Liming Xu (ORCID: https://orcid.org/0000-0001-9523-9062)
- Lu Zhang (ORCID: https://orcid.org/0000-0002-0860-9625)
- Yi Zhao (ORCID: https://orcid.org/0000-0002-6512-5096)
- Dongmei Han (ORCID: https://orcid.org/0000-0003-1557-0789)
- Hao Jin (ORCID: https://orcid.org/0000-0001-8488-1527)
Institutions
- Tianjin Medical University Cancer Institute and Hospital (CN)
Publication Details
- Journal
- Translational Cancer Research
- Published
- 2025-10-01
- DOI
- https://doi.org/10.21037/tcr-2025-704
- Citations
- 1
- Primary Topic
- PI3K/AKT/mTOR signaling in cancer
- Type
- article
- Field-Weighted Citation Impact
- 0.81